Wang Shanshan, Li Bin, Chen Qiong, Wang Chune, Wang Bin, Ye Qiang, Xu Yinghua
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes of Food and Drug Control, Beijing, People's Republic of China.
Hum Vaccin Immunother. 2025 Dec;21(1):2460274. doi: 10.1080/21645515.2025.2460274. Epub 2025 Jan 30.
Invasive pneumococcal disease (IPD) is a serious global public health problem and the leading cause of morbidity and mortality in children and adults in China. Thus, developing and administering pneumococcal vaccines are important for disease prevention. The PPV23 and PCV13 vaccines are available in the Chinese market and are primarily produced by domestic manufacturers. The potential risk of increased IPD caused by non-vaccine serotypes should be considered. Here, we review the current status of IPD, pneumococcal vaccines, and their quality control in China. We also address the challenges and future directions for making progress in controlling IPD, emphasizing the need for further evaluation of the disease burden and monitoring the effectiveness of vaccination efforts.
侵袭性肺炎球菌疾病(IPD)是一个严重的全球公共卫生问题,也是中国儿童和成人发病和死亡的主要原因。因此,研发和接种肺炎球菌疫苗对疾病预防至关重要。23价肺炎球菌多糖疫苗(PPV23)和13价肺炎球菌结合疫苗(PCV13)在中国市场均有供应,且主要由国内制造商生产。应考虑非疫苗血清型导致IPD增加的潜在风险。在此,我们综述了中国IPD、肺炎球菌疫苗及其质量控制的现状。我们还探讨了在控制IPD方面取得进展所面临的挑战和未来方向,强调需要进一步评估疾病负担并监测疫苗接种工作的效果。